Phase III Trial Oversight Should Rely On Adverse Event "Summaries," CRO Association Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Association of Clinical Research Organizations supports using partially blinded data summaries to help institutional review boards overseeing multi-center trials